Acutaas Chemicals Ltd Q3 FY2023 Concall Summary

Key Takeaways

• Deferred shipments mask underlying momentum: Reported revenue grew 8% YoY, but adjusted for 10–15 day shipment delays it would have been 15%; those sales land in Q4.
• Margin recovery is sequential and visible: EBITDA margin expanded 210 bps from Q1 to 20.2% in Q3, with management guiding another 1–1.5% quarterly improvement toward FY21 levels.
• Fermion deal is a decade-long anchor: A multi-year, multi-ton, multi-million-euro exclusivity contract for a brand-new launch product, with commercial supplies starting Q4 FY24.
• Electrolyte additives are at the inflection point: Samples with nine customers, one trial order received, and commercialization expected in Q1 or Q2 FY24 after a long gestation.
• What to watch next quarter: Whether the 35–40% Q4 growth needed to hit the full-year 25% target materializes, the pace of speciality chemicals margin improvement, and any commercial order for electrolyte additives.

The Deferred-Revenue Quarter

• What happened: Intermediates from China did not arrive in time for API manufacturers, who then chose not to hold high year-end inventory; shipments planned in December slipped 10–15 days into January, pulling roughly 7 percentage points of growth out of Q3 and into Q4.
• The adjusted picture: 9-month growth was ~15% reported and ~16% adjusted for the deferral; the full-year 25% target implies a very strong Q4, north of 35–40% growth.
• Volume-led pharma: All pharma growth came from volume; some older products saw price declines while others were flattish.
• Utilization optics: Pharma utilization at 60–64% and speciality chemicals at 35–40% appear flat, but flow reactor adoption released 6–7% utilization that would otherwise have pushed pharma to 72% and speciality chemicals to 40–45%.

Naresh Patel: "See FY23, as we say is that we are expecting and we are trying for the CAGR 25%. ... In FY24, similarly, we will remain in expectation of CAGR of 25%."

Margin Walk & Cost Reset

• Gross margin pressure: Fell to 46% due to high-cost inventory and a shift in product mix; most of that high-cost inventory was consumed in Q3, with only a minimal leg remaining in Q4, and Q1 FY24 will be a clean quarter.
• Sequential EBITDA climb: Margins moved from 18.1% (Q1) to 19.1% (Q2) to 20.2% (Q3), driven by lower freight and utility costs plus cost-optimization programs.
• Q4 margin tailwinds: Theoretically, margins should improve substantially on operating leverage from higher sales, softening raw material and freight costs, and lower purchase costs.
• Inventory discipline: The company reduced inventory stocking after a bad experience holding long inventory, aiming to avoid future margin hits from high-cost carry.
• One-time item: Other expenses included a ₹2.45 crore shortfall on an insurance claim related to a small stock fire in February 2021, recognized upon receipt of the claim in Q3.
• Interest-cost optics: A substantial QoQ increase in financial expenses reflects arbitrage: the company obtained finance at a lower rate and kept investments at a higher rate, which also lifted other income.

The Fermion Anchor Deal

• Structure: A multi-year, multi-ton, multi-million-euro contract for one of Fermion’s patented products, a brand-new launch molecule with 10-year exclusivity; Fermion will remain the sole supplier globally.
• Timeline: Three validation batches ship in Q4 FY23; a lean period for customer qualification follows; regular commercial supplies start Q4 FY24, served from new Ankleshwar capacity and initially supported by Unit 1 Surat.
• Economics: CMO-type work, so not very high margin, but operating leverage will come as commercial volumes scale; margins are expected in line with or slightly better than current levels.
• Scale undisclosed: Management declined to disclose run-rate numbers, citing that Fermion is also a listed company and both parties are bound by confidentiality.

Naresh Patel: "This contract, the numbers I can't say because the counterparty is also a listed Company. So, we both are bound with several bindings. So, the thing is that this is a very brand-new launch product and having exclusivity with them for the next 10 years."

Electrolyte Additives: Approaching Commercialization

• Status: Samples sent to nine customers; one has placed a qualification order, validating product quality and stability; management believes the long gestation period is at its tail end.
• Commercialization timeline: Q4 FY23 is ruled out; confident of commercial orders in FY24, possibly Q1 or Q2 depending on customer approval procedures; smaller manufacturers may qualify faster.
• Full ramp-up: If everything goes well, full commercialization by Q2 FY25; ramp-up will be gradual as customers will not immediately shift all weightage from China to India.
• Market sizing: At full scale, the business could be similar to Ami’s current size; the current market is ₹120 crore growing to ₹200–250 crore, with the company targeting a conservative share.
• Capacity readiness: Land already acquired; dedicated plant construction will start in FY24, taking 6–9 months to a year; the trigger is a green signal from a major buyer.
• Partnership: ARZ (Israel-based) is the exclusive worldwide marketing partner for electrolyte additives under a separate 2022 agreement.

Naresh Patel: "So, far, we have sent our electrolytes additives to nine customers and one of them has already asked for the trial order, which validates our products quality and stability. ... the gestation period to commercialize this product is fairly long, and I believe we are at the tail end of this period."

Speciality Chemicals: The Margin Rebuild

• Current state: The segment was subdued due to lower sales of the top product; margins were flat at around 10%.
• The transformation lever: The company is converting production from batch to continuous/flow technology, starting with methyl salicylate; flow reactors were installed in Q3, and samples have been sent to vendors with a ramp-up expected over the next 2–3 quarters, contributing 2–3% to EBITDA.
• Cost-side levers: A fuel-conversion project at Jhagadia (furnace oil to coal) has started, and operational improvements are underway to make the paraben business more competitive, though the roadmap remains confidential.
• Customer build: 39 new customers were added in Q4, the majority on the speciality chemicals side.

Naresh Patel: "See, yield improvement and all is like confidential matter, but definitely continuous production will help you in terms of operational efficiency as well as in terms of better-quality effluent generation, better safety."

Growth Engine: Pipeline & Patent Expiry

• Product-launch cadence: 15–20 products commercialize every year (range 8–20); new molecules deliver 30–40% growth while older products contribute 7–10% incremental growth annually, underpinning the 24–25% CAGR confidence.
• Patent-expiry tailwind: Billions of dollars of patented products going off patent this year and in coming years will create immense opportunity for the advanced pharmaceutical intermediate business; the company already has many of these products in its basket.
• Import substitution: Two already-commercial products continue to show strong traction; two others developed this year have received trial orders; one more product is set for commercialization in this segment.
• Segment reclassification: The company now reports broadly two segments: Pharma and Speciality Chemicals; products supplied to pharma as advanced pharma intermediates classify under pharma intermediates.

Naresh Patel: "Every year, 15 to 20 products are getting into the commercialization... our growth is maintained with this new incoming molecules which give us good growth, like 30%, 40%, whereas our very old product give us 7% to 10% of the incremental growth annually... this is how we are more confident about our growth guidance of 24%, 25% CAGR because of this kind of product pipeline, existing product and old products."

Guidance & Commitments

Key Metrics